Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea®, in Europe further strengthening the Company's growing biosimilars portfolio and expanding its presence in ophthalmology. The launch reflects Teva's strategy to build a leading biosimilars business in areas of significant patient need and to broaden access to biologic medicines through strong partnerships, broad commercial capabilities, and reliable supply.  

The launch of AHZANTIVE pre-filled syringes began in May 2026 across several European markets, including France, Germany, Spain, and The Netherlands.  The launch supports broader availability of biosimilar treatment options for patients living with serious retinal diseases and provides healthcare professionals with additional high-quality therapeutic choices. Teva expects to launch in additional markets later this year. The launch follows Teva's semi-exclusive commercialization agreement with Klinge Biopharma GmbH and Formycon AG in major parts of Europe and Israel.